Recent advances in mineralocorticoid receptor antagonists for heart failure with preserved ejection fraction: focus on finerenone in the era of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists
Tian-Yu Wang, Lei Zhang, Huan-Yi Wang, Fen-Fen Jiang · 2025
Read Recent advances in mineralocorticoid receptor antagonists for heart failure with preserved ejection fraction: focus on finerenone in the era of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists by Tian-Yu Wang, Lei Zhang, Huan-Yi Wang, Fen-Fen Jiang (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12747910.txt.
Description
Wang and co-authors review the case for finerenone, a newer hormone-blocking drug, in heart failure where the heart still pumps with preserved strength. This form of heart failure has tangled causes and few proven treatments. Overactive mineralocorticoid receptors help drive it, and blocking them is the strategy under review.
Finerenone is a non-steroidal blocker, more selective than older drugs such as spironolactone, with stronger anti-scarring and anti-inflammatory action in early studies. Kidney trials in diabetes first showed heart and kidney benefits, and the FINEARTS-HF trial extended the gains to this heart failure group. The review also weighs pairing finerenone with two other modern drug classes and surveys trials now under way. The authors call for a direct head-to-head trial against spironolactone with heart outcomes as the main measure.
Catalog record
| CREATOR | Tian-Yu Wang, Lei Zhang, Huan-Yi Wang, Fen-Fen Jiang |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 54 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |